SCHEMBL2477952

SCHEMBL2477952

Nc1ccccc1NC(=O)c1ccc(C(CCCN2CCOCC2)NC(=O)Nc2ccc(OC(F)F)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.47
PIK3CA P42336 3/20 0.47
HDAC1 Q13547 8/20 0.45
HDAC4 P56524 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
EPHX2 P34913 5/20 0.45
POLB P06746 1/20 0.43
TACR2 P21452 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
BCL3 P20749 1/20 0.42
EPHA2 P29317 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476882 0.90 HDAC3 (0.51) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2478730 0.88 HDAC1 (0.49) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2473466 0.88 HDAC1 (0.61) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL4390020 0.86 PIK3CA (0.48) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL4396311 0.85 HDAC1 (0.50) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL3833732 0.85 HDAC1 (0.51) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2473928 0.85 HDAC1 (0.47) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2474349 0.85 EGFR (0.49) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2473979 0.85 HDAC1 (0.47) HDAC3PIK3CAHDAC1HDAC4HDAC7
SCHEMBL2474116 0.84 HDAC1 (0.48) HDAC3PIK3CAHDAC1HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP claimed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC3 795/4885PIK3CA 4533/4885HDAC1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.